Latest News about NYSE:NNVC
Recent news which mentions NYSE:NNVC
   NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
   
  November 29, 2023
  Tags
   NYSE:NNVC
  
  From News Direct
 
   Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
   
  
  September 27, 2023
  Tags
   NYSE:NNVC
  
  From News Direct
 
   SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
   
  
  July 19, 2023
  Tags
   NYSE:NNVC
  
  From News Direct
 
   NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst
   
  July 13, 2023
  Tags
   NYSE:NNVC
  
  From News Direct
 Tags
   NYSE:NNVC
  
  From News Direct
 Tags
   NYSE:NNVC
  
  From News Direct
 Tags
   NYSE:NNVC
  
  From News Direct
 Tags
   NYSE:NNVC
  
  From News Direct
 Tags
   NYSE:NNVC
  
  From News Direct
 
   A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
   
  
  March 20, 2023
  Tags
   NYSE:NNVC
  
  From News Direct
 
   NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
   
  
  September 19, 2022
  Tags
   NYSE:NNVC
  
  From News Direct
 
   Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution
   
  August 10, 2022
  Tickers 
   SIGA
  
  Tags
   NYSE:NNVC
  
  From News Direct
 Tickers 
   NNVC
  
  
  From InvestorPlace
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 

